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The newly discovered trace amine-associated receptor 1 (TAAR1) has the ability to
regulate both dopamine function and psychostimulant action. Here, we tested in rats the
ability of RO5203648, a selective TAAR1 partial agonist, to modulate the physiological
and behavioral effects of methamphetamine (METH). In experiment 1, RO5203468
dose- and time-dependently altered METH-induced locomotor activity, manifested as
an early attenuation followed by a late potentiation of METH’s stimulating effects. In
experiment 2, rats received a 14-day treatment regimen during which RO5203648 was
co-administered with METH. RO5203648 dose-dependently attenuated METH-stimulated
hyperactivity, with the effects becoming more apparent as the treatments progressed.
After chronic exposure and 3-day withdrawal, rats were tested for locomotor sensitization.
RO5203648 administration during the sensitizing phase prevented the development
of METH sensitization. However, RO5203648, at the high dose, cross-sensitized with
METH. In experiment 3, RO5203648 dose-dependently blocked METH self-administration
without affecting operant responding maintained by sucrose, and exhibited lack of
reinforcing efficacy when tested as a METH’s substitute. Neurochemical data showed
that RO5203648 did not affect METH-mediated DA efflux and uptake inhibition in striatal
synaptosomes. In vivo, however, RO5203648 was able to transiently inhibit METH-induced
accumulation of extracellular DA levels in the nucleus accumbens. Taken together, these
data highlight the significant potential of TAAR1 to modulate METH’s neurochemical and
behavioral effects.
Keywords: trace amine-associated receptor, methamphetamine, sensitization, self-administration, synaptosomes,
microdialysis
INTRODUCTION
Methamphetamine (METH) is a widely abused and highly addic-
tive psychostimulant drug. In the brain, METH elevates extra-
cellular dopamine (DA) levels, an effect that is thought to
underlie its potent motor and psychoactive actions (Fleckenstein
et al., 2007). METH competes with DA for reuptake and causes
reverse transport through the DA transporter (DAT) (Elliott and
Beveridge, 2005; Goodwin et al., 2009). In addition, metham-
phetamine depletes monoamines from vesicular storage through
the vesicular monoamine transporter-2 (VMAT2), resulting in
increased DA in the cytoplasm available for reverse transport by
the DAT (Sulzer et al., 2005; Fleckenstein et al., 2009). Apart
from its direct interaction with the DA system, METH is also a
potent agonist at the trace amine-associated receptor 1 (TAAR1)
(Bunzow et al., 2001; Reese et al., 2007). TAAR1 belongs to a
family of G-protein coupled receptors that is activated by trace
amines (TAs), a group of endogenous amines often referred to
as “endogenous amphetamines” due to their ability to increase
monoamine release via displacing monoamines from synaptic
vesicles and reversing monoamine transporters on the plasma
membrane (Berry, 2004). TAs have been implicated in brain
reward and in the reinforcing properties of psychostimulants
(Gilbert and Cooper, 1983; Shannon and Thompson, 1984),
albeit their independent role as neurotransmitters was not recog-
nized until TAAR1 was discovered and characterized (Borowsky
et al., 2001; Bunzow et al., 2001). TAAR1 shares overlapping dis-
tribution in the brain with mesolimbic DA pathways (Borowsky
et al., 2001; Lindemann et al., 2008), is co-localized with the DAT
in a subset of DA neurons (Xie and Miller, 2007), and interacts
with both the DAT and the D2 DA autoreceptor (D2R) to modu-
late DA transmission (Xie et al., 2007, 2008; Espinoza et al., 2011).
These observations suggest that TAAR1 regulates DA activity and
has the potential to serve as a pharmacological target to modulate
DA dysregulation that results from chronic stimulant exposure.
Early evidence supporting the potential of TAAR1 to con-
trol DA function comes from studies on Taar1 knock-out mice
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which showed an elevated spontaneous firing rate of DA neu-
rons in the ventral tegmental area (Lindemann et al., 2008) and
increased DA release in the NAc (Leo et al., 2014), suggesting that
TAAR1 is constitutively active or tonically activated by ambient
levels of amines, including TAs, to negatively regulate DA activ-
ity. Those mutant mice also displayed enhanced sensitivity to
psychostimulant-induced locomotor activity, conditioned place
preference (Achat-Mendes et al., 2012) and striatal DA release
(Wolinsky et al., 2007; Lindemann et al., 2008), supporting the
role of TAAR1 in psychostimulant action. The recent develop-
ment of several selective TAAR1 agonists has enabled a more
direct assessment of TAAR1 functionality. While the TAAR1 full
agonists, RO5166017 (Revel et al., 2011) and RO5256390 (Revel
et al., 2012a), were able to inhibit the firing rate of dopamin-
ergic neurons in the ventral tegmental area, the TAAR1 par-
tial agonists, RO5203648 (Revel et al., 2012b) and RO5263397
(Revel et al., 2012a), and the antagonist, EPPTB (Bradaia et al.,
2009), increased their firing frequency, demonstrating a strong
modulation of DA activity by TAAR1 activation.
More recent studies have focused on examining the
therapeutic-like effects of TAAR1 agonists on cocaine addiction.
It was found that TAAR1 activation suppressed cocaine-induced
locomotor hyperactivity (Revel et al., 2012b), behavioral sensi-
tization and conditioned place preference (Thorn et al., 2014),
and reduced cocaine self-administration (Revel et al., 2012b;
Thorn et al., 2014), suggesting a blockade of both acute psy-
chostimulating and long-term psychomotor sensitization effect
of cocaine as well as cocaine’s reinforcing property through
pharmacological activation of TAAR1. Moreover, the two partial
agonists, RO5203648 (Pei et al., 2014) and RO5263397 (Thorn
et al., 2014) were able to block cocaine relapse, further sup-
porting the development of TAAR1-based pharmacotherapies
in cocaine addiction. Data on potential interactions between
METH and TAAR1 is much more limited. METH and cocaine
have different actions on DAT with the former producing strong
DA releasing effects. More importantly, while TAAR1 has no
affinity for cocaine, activation of TAAR1 by METH results in
inhibition of DA uptake, enhancement of DA efflux and DAT
internalization (Xie and Miller, 2009). The present work was
aimed at further characterizing the effects of TAAR1 activation
on key METH-related behavioral and neurochemical changes.
We tested the ability of the partial agonist, RO5203648, to
modulate METH-induced locomotor activity and behavioral
sensitization, METH self-administration and substitution, and
METH-stimulated striatal DA efflux in vitro and in vivo.
MATERIALS AND METHODS
SUBJECTS
Male Long Evans rats were sourced from the University of
Canterbury, the University of Otago and the Italian Institute of
Technology and were 8–10 weeks-old when experiments began.
Rats were generated from outbred stocks, with rats from differ-
ent institutions or suppliers not bearing any direct relationship.
For the behavioral experiments, all animals were housed in a
temperature and humidity controlled colony room with a 12-
h light/dark cycle (lights off at 8 a.m.). Water and standard
laboratory rat chow was given ad libitum at all times in all
experiments except in the self-administration (S-A) experiment
in which rats were given a maintenance diet (i.e., kept at
100% of their weight 7 days post-surgery) (Velazquez-Sanchez
et al., 2011, 2013). To perform the [3H]dopamine uptake and
efflux assays synaptosomes were prepared from brains of Wistar
rats (F. Hoffmann-La Roche Ltd., Basel, Switzerland). Animal
care and experimental protocols were conducted in compliance
with the New Zealand Animal Welfare Act 1999, the Italian
Ministry of Health (DL 116/92; DL 111/94-B) and European
Community (86/609/EEC) directives, and the Swiss Federal and
Basel Cantonal laws on animal research. All experiments were
approved by the ethics committee affiliated to each institution.
Power analysis was conducted as part of the applications for ethics
approval to estimate the number of animals required per experi-
ment, with α set at 0.05 and power at 90%. Data from all animals
was included in the statistical analyses.
PHARMACOLOGICAL AGENTS
Methamphetamine hydrochloride was obtained from BDG
Synthesis (Wellington, New Zealand) and dissolved in 0.9% phys-
iological saline for intraperitoneal (i.p.) injection and intravenous
S-A. RO5203648 (partial TAAR1 agonist) was synthesized at
F. Hoffman-La Roche Ltd. (Switzerland) and dissolved in 10%
dimethylsulfoxide and 0.9% physiological saline.
CATHETER IMPLANTATION SURGERY
Rats used for the S-A experiment were anesthetized with Avertin
(2,2,2-tribromoethanol, 12.5mg/ml, in 2.5% tertiary amyl alco-
hol, 2ml/100 g of body weight, i.p.). The analgesic carpro-
fen was administered before surgery (5mg/kg, i.p.). Catheters
(O/D 0.63mm, I/D 0.30mm, Camcaths Cambridge, UK) were
implanted into the right jugular vein, exiting dorsally between the
scapulae. Analgesic and antiseptic cream was applied to the back
and neck incision areas following suturing. To prevent infection
rats were treated post surgically with daily injections of antibiotic
(Cephalexin, 10mg/kg, s.c.) for 7 days. Catheters were flushed




Locomotor activity experiments were conducted in a set of four
open field boxes made of black Perspex (50 × 40 × 35 cm).
Locomotor activity was monitored and measured with a video
tracking system and image analysis software (Viewpoint 2.5,
Champagne au Mont D’Or, France) that provided automatic
measures of traveled distance, trajectory and velocity of the
subjects.
Six groups of rats (n = 5–6 per group) were habituated in the
open field for 10min for two consecutive days. During the test,
rats were given a pretreatment of RO5203648 (0, 5, 10mg/kg,
i.p.) followed 15min after by METH (0, 0.75mg/kg, i.p.). 10min
after METH treatment, rats were placed into the open field
and locomotor activity was measured for 3 h. Four rats were
tested concurrently in four separate open fields. Locomotor activ-
ity was estimated as distance traveled and recorded in 20min
bins.
For the sensitization experiments, six groups of rats (n = 5–6
per group) were habituated to the open field during 30min
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on two consecutive days. Because this experiment assessed the
chronic effects of RO5203648 and METH, the doses selected were
lower than that used in the 3-h locomotor experiment described
above. During the 14 days sensitization period, rats received daily
treatment of RO5203648 (0, 1.67, 5mg/kg, i.p.) followed 10min
after by METH (0, 0.75mg/kg, i.p.) and were allowed to freely
explore the open field for 60min. Four rats were tested con-
currently in four separate open fields. Locomotor activity was
recorded on alternate days. Treatments were administered in the
home cages on the no-test days. Rats underwent withdrawal from
all pharmacological treatments for three consecutive days before
receiving a challenge with a low dose of METH (0.25mg/kg, i.p.)
to probe for sensitization. Locomotor activity was recorded for
60min in the sensitization test.
S-A experiments
Eight operant conditioning chambers (Panlab, SL, Barcelona,
Spain) controlled by software (Packwin software package) were
used in the S-A experiments. Chambers were equipped with two
response levers, an infusion pump, a house light and a stimu-
lus light. Presses on the active lever resulted in activation of the
infusion pump and delivery of METH or saline, illumination of
a light stimulus for 5 s and initiation of a 20 s time-out. Presses
on the inactive lever were recorded but had no programmed con-
sequences. Each experimental chamber was enclosed in a light-
and sound-attenuating box. The house light was on throughout
training and test sessions.
After surgery, rats were randomly assigned to METH (n = 10)
and saline groups (n = 6) and were trained to receive METH
(0.05mg/kg/infusion) or saline infusions under a fixed ratio (FR)
1 reinforcement schedule in daily 60min sessions. METH intake
tests began after the rats in the METH group met a criterion
of consistency and stability (number infusions per session ≥15
for three consecutive days with less than 20% variability). Each
rat completed three METH-taking tests on alternate days dur-
ing which a pre-treatment of RO5203648 (0, 3, 10mg/kg, i.p.)
was administered 10min before the self-administration session.
The order in which treatments were administered was counter-
balanced between subjects. After completion of all three tests rats
were re-exposed to standard METH or saline self-administration
sessions.
After the rats in the METH group returned to stable
responding (number infusions per session ≥15), we tested self-
administration of the TAAR1 partial agonist to examine its
reinforcing properties. Each rat underwent four substitution
tests in which varying doses of RO5203648 were given through
intravenous infusions (0, 0.25, 0.5, and 1mg/kg/infusion).
Substitution tests were conducted on separate 60min sessions,
one for each dose, on alternate days. The order of the four
tests was fully randomized. After all four substitution tests
were carried out, rats completed a test in which the self-
administered solution was replaced by a dose of METH three
times weaker than the training dose (0.017mg/kg/infusion;
training dose was 0.05mg/kg/infusion). This test was done in
order to ascertain that the rats remained sensitive to vari-
ations in the reinforcing efficacy of the drug available for
self-administration.
To test for potential nonspecific effects of RO5203648 on gen-
eral motivation and performance rats were trained on saccharin
(0.1%) self-administration. After two sessions of stable respond-
ing (≥15 reinforcements per session), each rat was tested three
times, receiving a pretreatment of RO5203648 (0, 3, 10mg/kg
i.p.), administered in a counterbalanced fashion 10min before the
saccharin self-administration session started.
SYNAPTOSOME [3H]DA UPTAKE AND EFFLUX ASSAYS
Wistar rats were sacrificed at 12 weeks of age to collect brain
samples. This strain was used because of the availability and
reliability of standards on our extensive database and consis-
tent results with a range of psychomotor stimulants. For each
synaptosomal preparation we pooled 5 rat brains. Each experi-
ment was performed in 3 technical replicates and 3–5 biological
replicates. The striatum was dissected out and homogenized in
20 vol buffer A (0.32M sucrose, 4mM Hepes/NaOH, pH 7.4,
5mM DTT, 1mM EDTA and complete protease inhibitor) with
a homogenizer using ceramic beads (Minilyser, Bertin technolo-
gies, France). The homogenate was centrifuged at 800 × g at 4◦C
for 10min and the supernatant was kept. The pellet was resus-
pended in 5 vol buffer A and centrifuged again under the same
conditions. Supernatants were pooled and centrifuged at 9000× g
at 4◦C for 20min. The pellet was resuspended in 10 vol buffer A
and centrifuged again under the same conditions. The pellet was
resuspended in 1ml/brain recovery cell culture freezing media
(LuBioScience, Lucerne, Switzerland). Protein concentration was
determined and stored at −80◦C until needed.
On the day of the uptake assay, striatal synaptosomes were
washed in Krebs–Hepes buffer, incubated for 20min at room
temperature with various concentrations of METH (0.00003–
30μM) with or without co-application of 3μM RO5203648,
or with various concentrations of RO5203648 alone (0.00003–
30μM). The synaptosomes were then incubated with DA tracer
for 10min. After rigorous washing with PBS, scintillator (Perkin
Elmer, Schwerzenbach, Switzerland) was added and the uptake of
[3H]DA was detected with a liquid scintillation analyzer (TopLab,
Switzerland).
For the efflux assay, synaptosomes were preloaded with
[3H]DA and incubated in Krebs–Hepes buffer at 25◦C for 20min.
After centrifuged at 4◦C for 3min (max speed), the synaptosomes
were resuspended in buffer containing different concentrations
of METH (0.3–10μM) with or without co-application of 3μM
RO5203648. The synaptosomes were then incubated at 25◦C for
45min, washed again with ice cold buffer, and centrifuged, as
previously, before scintillator was added and counted.
IN VIVO MICRODIALYSIS
In vivo microdialysis was performed in the right nucleus accum-
bens (NAc) of freely moving rats, using concentric microdialy-
sis probes (membrane length 2mm, cut-off 6000 Da; CMA-11,
CMA/Microdialysis, Solna, Sweden). Animals were anesthetized
with oxygen/isofluran mixture, and positioned in a stereotaxic
apparatus. Stereotaxic coordinates for probes position were cho-
sen according to the rat brain atlas: AP +1.7; L 1.4; DV −8.1
relative to bregma. Probes were implanted in the brain vertically
through small drilled aperture in the skull and fixed with dental
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cement. The dialysis probes were perfused during implantation
into the brain and for 1 h afterward with artificial cerebrospinal
fluid (aCSF) (NaCl 147mM, KCl 2.7mM, CaCl2 1.2mM, MgCl2
0.85mM; CMAMicrodialysis).
Approximately 24 h after surgery the dialysis probes were con-
nected to a syringe pump and perfused with aCSF at 1.0μl/min
for 60min (equilibration period) and then the perfusate was
collected at a perfusion rate of 1.0μl/min every 20min for at
least 60min into collection tubes containing 2μl of 1M per-
chloric acid (basal levels). After this period animals were injected
with vehicle, METH (0.75mg/kg, i.p.) or RO5203648 (5mg/kg,
i.p.) or received double injections with RO5203648 and METH
together (at the same doses) and the perfusate was collected at
a perfusion rate of 1.0μl/min every 20min over a 3 h period.
Quantification of DA in microdialysis samples was performed
using HPLC with electrochemical detection (ALEXYS LC-EC
system) equipped with a reverse-phase column (3μm parti-
cles, ALB-215 C18, 1 × 150mm, Antec Leyden BV, Netherlands)
at a flow rate of 200μl/min and electrochemically detected by
a 0.7mm glass carbon electrode (Antec; VT-03). The mobile
phase contained 50mM H3PO4, 50mM citric acid, 8mM KCl,
0.1mMEDTA, 400mg/l octanesulfonic acid sodium salt and 10%
(vol/vol) methanol, pH 3.9. The sensitivity of the method per-
mitted detection of ∼3 fmol DA. Dialysate samples (11μl) were
injected into HPLC without any purification.
STATISTICAL ANALYSIS
Data were analyzed by analysis of variance (ANOVA) with
repeated measures when a within-subjects design was in use. Post-
hoc comparisons were conducted with the method of Newman–
Keuls (N–K) using the sampling error from the overall ANOVA
as denominator. Statistical significance was set at α = 0.05 for
all experiments. All statistical analyses were performed using
StatView 5.0 (SAS Institute, NC, USA).
RESULTS
RO5203648 BLOCKS METH-INDUCED LOCOMOTOR SENSITIZATION
Rats were chronically treated with RO5203648 (0, 1.67, 5mg/kg,
i.p.), administered 15min before METH (0, 0.75mg/kg, i.p.), and
locomotor activity was measured on alternate days. RO5203648
significantly attenuated locomotor sensitization induced by
repeated METH treatment (Figure 1A). A repeated measure
ANOVA yielded a significant main effect of drug treatment
(F5, 28 = 26.68, p < 0.0001) and a significant interaction effect
between the factors drug treatment, session (1 through to 7)
and time (twelve 5min time bins) (F330, 1848 = 1.19, p < 0.019).
Post-hoc comparisons showed that METH significantly enhanced
locomotor activity as treatments progressed, with activity of the
7th test being significantly higher compared with the 1st (p <
0.01, by N–K tests). The ability of RO5203648 to attenuate the
effects of METH gradually increased across sessions. Both doses
of RO5203648 were effective at reducing METH-induced loco-
motor activity (p < 0.05 for session 2 and 4, p < 0.01 for sessions
5 through to 7) and preventing METH sensitization during the
acquisition phase (Figure 1A).
After 14 days sensitization treatment and 3-day withdrawal
rats received METH (0.25mg/kg, i.p.) and locomotor activity was
evaluated. Previous repeated METH exposure in the sensitiza-
tion phase led to a significantly heightened response to METH
administration, which was significantly attenuated by RO5203648
(Figure 1B). ANOVA revealed a significant effect of treatment
(F5, 28 = 3.27, p = 0.0189). Post-hoc comparisons indicated that
rats with a history of chronic METH treatment showed signif-
icantly higher locomotor activity comparing to controls (p <
FIGURE 1 | Modulation of METH-induced locomotor activity and
sensitization by TAAR1. (A) Chronic exposure to methamphetamine
gradually increased locomotor activity. Low and moderate doses of
RO5203648 attenuated METH-induced locomotor activity and blocked the
progressive increment induced by repeated exposure to METH. (B)
Following withdrawal from chronic METH exposure, a challenge with a low
dose of METH produced sensitized locomotor responsiveness. The
long-term expression of locomotor sensitization was prevented in rats that
had received concurrent treatment with RO5203648 (at either low or
moderate doses) and METH. Treatment with the high dose of RO5203648
alone during the sensitization phase enhanced the subsequent long-term
response to METH. (C) METH produced robust increases in locomotor
activity compared with control treatment in a 3-h activity test. RO5203648
produced an early attenuation and a late potentiation of METH-stimulated
locomotor activity. ϕp < 0.01, different from acute METH (day 1); #p < 0.01,
different from chronic METH (day 7), ∗p < 0.01 different from METH (after
chronic control treatment), φp < 0.01 different from METH (after chronic
METH exposure). RO = RO5203648, MA = methamphetamine.
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0.01, by N–K tests). This sensitized response was significantly
reduced by both doses of RO5203648 (p < 0.01, by N–K tests).
Moreover, RO5203648 treatment alone at the high dose, but not
the low dose, produced significant cross-sensitization in the probe
test as revealed by post-hoc comparisons (p < 0.01 comparing to
control, by N–K tests).
RO5203648 TIME-DEPENDENTLY MODULATES METH-INDUCED
LOCOMOTOR ACTIVITY
To study the interactions between RO5203648 and METH
across time, locomotor activity induced by these treatments was
examined for 3 h in an open field following single and combined
administration. Rats received a pre-treatment of RO5203648
(0, 5 or 10mg/kg, i.p.) 15min before METH (0 or 0.75mg/kg,
i.p.). RO5203648 altered the effects of METH on locomotor
activity in a time-dependent fashion, producing an early attenu-
ation followed by a striking late potentiation. Locomotor activity
was analyzed by repeated-measure ANOVA, which showed
a significant effect of treatment (F5, 29 = 15.80, p < 0.0001)
and time (F8, 232 = 15.94, p < 0.0001), as well as a significant
interaction between these factors (F40, 232 = 8.35, p < 0.0001)
(Figure 1C). METH produced high levels of locomotor activity
in the first 20min that decreased gradually over the 3 h test.
RO5203648 significantly attenuated METH-induced hyperloco-
motion during the first hour at both the low and the high doses
(p < 0.01 for the 1st–3rd bins, by N–K tests). However, as the
effect of METH treatment alone slowly subsided, RO5203648
potentiated METH’s effects by maintaining locomotor activity
at a moderately high levels, which were significantly higher than
that produced by METH alone at both the low (p < 0.05 for the
6th bin, p < 0.01 for the 7–9th bins, by N–K tests) and the high
dose of RO5203648 (p < 0.05 for the 5th bin, p < 0.01 for the
6–9th bins, by N–K tests).
RO5203648 BLOCKS METH, BUT NOT SACCHARIN
SELF-ADMINISTRATION, AND LACKS REINFORCING EFFICACY
We then tested the ability of RO5203648 to attenuate METH S-A.
Rats trained to self-administer METH under a FR1 schedule of
reinforcement obtained a significantly higher number of infu-
sions than rats responding for saline (n = 6) (F1, 11= 34.45,
p = 0.0001) (Figure 2A). Pre-treatment with RO5203648 (0, 3,
10mg/kg, i.p.) significantly attenuated METH S-A (Figure 1B).
ANOVA revealed a significant main effect of drug (METH
vs. saline, F1, 10 = 23.39, p = 0.0007) and dose of RO5203648
(F2, 20 = 12.12, p = 0.0004), as well as a significant interaction
between those factors (F2, 20 = 9.74, p = 0.0011). Post-hoc com-
parisons indicated significant effects of both doses of RO5203648
on the number of METH infusions obtained (p < 0.01, by N–K
tests) (Figure 2B). The number of infusions obtained by the
control group remained low and was not affected by RO5203648.
To control for potential motoric and motivational confounds,
we tested the effects of RO5203648 on responding maintained by
a natural reinforcer (saccharin). Pre-treatment with RO5203648
(0, 3, 10mg/kg, i.p.) 10min before the saccharin S-A session did
not affect responding as revealed by a repeated measures ANOVA
(p = 0.639) (Figure 2C).
To test the abuse potential of RO5203648, we substituted
METH for RO5203648 in the S-A task. Rats received infusions
of RO5203648 at different doses (0, 0.25, 0.5, 1.0mg/kg/infusion,
i.v.) on separate tests. In the final test rats worked for METH
infusions (0.017mg/kg/infusion). One-way ANOVA revealed a
significant effect of the self-administered drug (F4, 24 = 11.67,
p < 0.0001) (Figure 2D). Post-hoc comparisons showed that S-A
of different doses of RO5203648 did not generate varying levels of
responding over and above S-A of saline. However, S-A of METH
maintained significantly elevated rates of responding compared
with RO5203648 and saline infusions (p < 0.01, by N–K tests),
with the number of METH infusions at the low dose being 2-fold
greater than that obtained with the training dose (Figure 2B).
RO5203648 HAS NO EFFECT ON METH-INDUCED DA RELEASE OR
INHIBITION OF DA UPTAKE IN THE STRIATUM IN VITRO
In order to investigate the impact of TAAR1 partial agonism
on METH-induced DA release and uptake, striatal synapto-
somes were stimulated with various concentrations of METH to
FIGURE 2 | RO5203648 decreases METH S-A and exhibits reduced
abuse liability in a substitution test. (A) Rats were trained on METH
S-A until consistent performance was attained. (B) RO5203648
dose-dependently reduced METH S-A but did not affect sucrose S-A
(C). (D) In a substitution procedure, varying concentrations of
RO5203648 did not sustain S-A behavior over and above control values,
whereas a concentration of METH three times lower than that used
during training generated strong responding. ∗p < 0.01, different from
control values; #p < 0.01, different from METH. RO = RO5203648, MA
= methamphetamine.
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elevate synaptic levels of DA. METH-induced increases in DA
transmission were not affected by the co-application of 3μM
RO5203648, as revealed by a two-way ANOVAwhich showed only
a significant main effect of the METH treatment (F3, 14 = 4.56,
p = 0.0199) (Figure 3A). In the uptake assay, METH induced a
significant inhibition of DA uptake in a concentration-dependent
manner. Similarly, uptake inhibition was not altered by the co-
incubation with 3μM RO5203648. RO5203648 alone also pro-
duced a weak DA uptake inhibition, but at a concentration (IC50
3μM) 10-folder higher than that produced byMETH alone (IC50
0.3μM). A Two-Way ANOVA revealed a significant main effect
of concentration (F10, 44 = 89.37, p < 0.0001) and a significant
main effect of treatment (F2, 44 = 34.23, p < 0.0001), as well as
a significant interaction between those factors (F20, 44 = 2.70,
p = 0.0030) (Figure 3B).
RO5203648 ATTENUATES METH-INDUCED CHANGES IN DA
TRANSMISSION IN THE NAc
To explore the mechanisms underlying the ability of RO5203648
to modulate METH-stimulated behaviors, we measured DA
outflow in the NAc using in vivomicrodialysis. Samples were col-
lected for 3 h at 20min intervals following treatment withMETH,
alone and in combination with RO5203648. A repeated measure
ANOVA revealed a significant effect of treatment (F3, 23 = 20.16,
p < 0.0001) and time (F9, 207 = 13.47, p < 0.0001), as well as
a significant interaction between these factors (F27, 207 = 5.35,
p < 0.0001). Post-hoc comparisons showed that METH produced
a significant increase in DA level, which reached peak level at
60min, followed by a decrease over time (p < 0.01 comparing to
control, for the 1st–6th bins, by N–K tests). RO5203648 blocked
the METH-induced increase in DA levels in the first 20min
after METH administration (p < 0.01 at 40min, by N–K tests)
(Figure 3C).
DISCUSSION
The present data provide extensive evidence of interactions
between METH and the TAAR1 partial agonist, RO5203648,
demonstrated in a range of behavioral paradigms and
neurochemical experiments, including tests of locomotor
activity, sensitization, self-administration, and in vivo microdial-
ysis. Taking together, the current data showed a significant ability
of TAAR1 to modulate the neurochemical and behavioral effects
of METH.
METH is known for its ability to potently increase extracel-
lular DA levels in the mesolimbic dopaminergic pathway, which
largely underlies its motor-stimulating and rewarding effects.
Following repeated exposure, METH produces long-lasting neu-
roadaptive changes in the mesolimbic DA system, characterized
by a progressive augmentation of stimulant-induced DA efflux,
which is thought to be a key neurochemical signature of METH
behavioral sensitization (Yamada et al., 1988; Nakagawa et al.,
2011). Our finding that repeated RO5203648 co-administered
with METH blocked the development of METH sensitization
suggests that TAAR1 is able to modulate the long-term neuroad-
aptations induced by chronic METH exposure. In line with these
observations, it has been shown previously that mice lacking taar1
were hypersensitive to the motor-stimulating effects of METH
(Achat-Mendes et al., 2012), suggesting that TAAR1 is either
constitutively active or tonically activated by ambient ligands to
suppress the dopaminergic response to METH. In the current
study, TAAR1 activation by RO5203648 may have exerted an
inhibitory control over METH-evoked DA transmission, thereby
preventing the induction of the dopaminergic hypersensitiv-
ity that underlies METH sensitization. Markedly complicating
this picture, however, is the fact that METH itself is a potent
full agonist at TAAR1, potentially leading to the initiation of
phosphorylation events that down-regulate DAT function result-
ing in extracellular DA accumulation (Xie and Miller, 2009).
Hence, alternatively or complementarily, RO5203648 may block
METH-induced excessive DA transmission through the TAAR1-
mediated pathway by directly competing with METH at TAAR1,
thereby attenuating the progression of dopaminergic sensitization
induced by repeated METH. Intriguingly, repeated RO5203648
alone, at moderate doses (5mg/kg), cross-sensitized with METH,
FIGURE 3 | RO5203648 transiently attenuated DA overflow in the NAc
in vivo but not in striatal synaptosomes. (A) In striatal synaptosomes the
efflux of [3H]DA induced by varying concentrations of METH was not affected
by co-application of RO5203648, aswas the uptake of [3H]DA (B) In the 3-h long
in vivomicrodialysis experiment RO5203648 delayed the strong increases in
extracellular DA accumulation induced by METH treatment in the NAc,
producing amarked transient inhibition of the DA response (C) please note that
a pure control cannot be included in the uptake experiments (B) because no
efflux or release can be measured after vehicle treatment. #p < 0.01, different
fromMETH. RO = RO5203648, MA = methamphetamine.
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suggesting that long-term treatment with the partial agonist may
have resulted in neuroadaptations in the mesolimbic DA system
that are similar to those evoked by chronic METH treatment.
Previous studies have shown that alterations of both D1 and D2
DA receptors play a key role in the development of stimulant sen-
sitization (Shuto et al., 2006; McGinty et al., 2008). Although
there is no evidence of direct interactions of TAAR1 with DA
D1 receptors, previous data hints at a complex inter-relationship
between TAAR1 and DA D2 receptors. Xie et al. (2008) demon-
strated cross-attenuation of signaling between TAAR1 and DAD2
receptors, with their signaling having opposite effects on intra-
cellular phosphorylation cascades and extracellular DA transmis-
sion (Xie et al., 2008). Additional findings revealed that taar1
knockout mice displayed up-regulation of high-affinity striatal
D2 receptors (Wolinsky et al., 2007) and reduced D2 receptor-
mediated auto-inhibition (Leo et al., 2014). Thus, it is possible
that intermittent partial activation of TAAR1 with RO5203648
alters the coordinated interactions between TAAR1 and DA D2
receptors or causes neuroadaptive changes in DA D2 recep-
tors, leading to altered auto-inhibitory control over dopamin-
ergic transmission. Alternatively or complementarily, repeated
TAAR1 activation may lead to persistent changes in glutamater-
gic transmission. Enhanced glutamatergic transmission in the
ventral tegmental area and nucleus accumbens plays a funda-
mental role in stimulant sensitization (Wolf, 1998; Vanderschuren
and Kalivas, 2000). The full TAAR1 agonist, RO5166017, pre-
vented the hyperactivity induced by NMDA receptor blockade
(Revel et al., 2011), suggesting that TAAR1 activation may facil-
itate glutamate neurotransmission. Importantly, at the low dose
(1.67mg/kg) RO5203648 did not cross-sensitize with METH but
maintained its ability to reduce METH sensitization. Therefore,
it would appear that at low doses the partial TAAR1 agonist is
able to block METH sensitization without inducing long-term
METH-like neuroadaptations.
To further investigate the interactions between TAAR1 and
METH, we conducted a 3-h locomotor activity test after acute
treatment with RO5203648, alone and combined with METH.
Early during the test RO5203648 produced a dose-dependent
attenuation of METH-induced hyperactivity, which is consis-
tent with our finding that partial TAAR1 activation attenuated
METH-evoked DA release. Interestingly, RO5203648 potentiated
the locomotor-enhancing effects of METH in the later phase of
the locomotor activity test, as METH’s effects began to decay.
Our attempt to gain insight into the neurochemical mechanisms
mediating this interaction was only partially successful. METH-
induced DA accumulation in the NAc seemed to be altered by
TAAR1 activation in biphasic fashion but the late potentiation
effect on DA overflow did not reach statistical significance. This
indicates that mechanisms other than net DA transmission at
NAc synapses are likely to contribute to the complex regulation of
METH-induced hyperactivity by TAAR1. Additionally, the later
increase in locomotion is unlikely to be explained by a gradual
temporal decay of RO5203648’s effects, which could potentially
allow the recovery of METH’s effects over time, since this bipha-
sic action of RO5203648 was also observed in a previous study
in which RO5203648 alone produced an early inhibition fol-
lowed by a later enhancement of food-maintained responding
(Pei et al., 2014). In the experiment by Pei et al. rats treated with
RO5203648 only (i.e., not combined with METH) responded for
food over and above control rats under a progressive ratio sched-
ule of reinforcement, with more responses accumulating long
after treatment (3–6 h after), suggesting that RO5203648 remains
psychoactive for several hours.
In the synaptosomal preparation RO5203648 did not affect
METH-induced striatal DA release and DA uptake inhibition,
suggesting that RO5203648 regulation of METH’s behavioral
effects is unlikely to depend on direct, local actions at the DAT.
As previously indicated, the in vivo microdialysis data revealed
transient but significant reduction in METH-induced DA over-
flow following RO5203648 treatment. The apparent discrepancy
between the in vitro and in vivo experiments could be explained
by the difference in concentrations used and the network effects
of systemic TAAR1 activation. Indeed, TAAR1 seems to exert
inhibitory control over the activity of DA-releasing neurons orig-
inating in the ventral tegmental area. The full TAAR1 agonist,
RO5166017, decreased the firing rate of mouse midbrain DA neu-
rons (Revel et al., 2011), whereas the effects of RO5203648 on
DA transmission appeared to be dependent on ambient levels of
endogenous agonists, including DA itself, given its partial ago-
nist profile (Revel et al., 2012b). The synaptosomal assays were
conducted with tissue that may have contained synaptic frac-
tions from dorsal striatum, thus potentially adding variability
to the assay. We also acknowledge the use of different strains
of rat for the synaptosomal assays and microdialysis experi-
ments. Thus, tissue-specific and strain-specific differences may
have contributed to these inconsistent results.
The current findings also demonstrated that RO5203648
dose-dependently attenuated METH self-administration, which
is likely to reflect a decrease in the reinforcing efficacy of METH,
although we acknowledge that we only tested METH S-A under a
FR1 schedule and at one dose (0.05mg/kg/infusion). Our data are
consistent with previous evidence indicating that the partial ago-
nist RO5263397 reduced self-administration of METH at doses of
METH that were both on the ascending and descending limbs of
the dose-response curve (Jing et al., 2014). Further, we showed
that the effect of RO5203648 on METH self-administration
could not be attributed to general motivational or motor deficits
because RO5203648 did not affect sucrose self-administration.
Previous studies have shown that RO5203648 decreased cocaine
self-administration and cocaine seeking at doses that did not
impair food-maintained responding (Revel et al., 2012b; Pei et al.,
2014). These observations are consistent with the finding that
taar1 deletion led to earlier acquisition and delayed extinction
of place preference induced by METH exposure (Achat-Mendes
et al., 2012), similarly suggesting an inhibitory control of TAAR1
over METH’s rewarding properties. Importantly, our data also
revealed that RO5203648 did not maintain significant levels of
S-A when it was substituted for METH, which may be indicative
of low abuse potential, a desirable feature for TAAR1-based phar-
macotherapies to have. On the basis of these data, and considering
that TAAR1 agonists have been shown to have clear therapeutic-
like effects in models of cocaine addiction (Pei et al., 2014; Thorn
et al., 2014), it may be tempting to speculate that such poten-
tial clinical application could be expanded to METH addiction.
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However, such generalization requires considerable caution given
the complexities revealed by the present results, especially those
that relate to long-term TAAR1 agonist treatment and behavioral
sensitization.
In summary, the present data revealed novel complex interac-
tions between the selective TAAR1 partial agonist, RO5203648,
and METH. These findings further demonstrate the potential
of TAAR1 to modulate stimulant-induced neurochemical and
behavioral effects and provide additional support for the inves-
tigation of TAAR1 as a target for therapeutic intervention in
addictive disorders.
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